Connecting European Neuroscience

Przewlocki, Ryszard

Chair Schools Programme Committee (2010 - 2014)

Personal Information

PRZEWLOCKI RYSZARD obtained a PhD in natural sciences in 1975. In 1991 he became a Full Professor in medical sciences, and has since served as a Head of Molecular Neuropharmacology Department at the Institute of Pharmacology, Polish Academy of Sciences in Krakow, Poland. He also holds a professorship at the Jagiellonian University in Krakow. From 1977 to1979 he was a postdoctoral fellow at the Max-Planck Institute of Psychiatry in Munich, and from 1995 to 1996 he was a Fulbright Fellow at the Scripps Research Institute in San Diego. He served as a President of the Polish Neuroscience Society. He was elected a member of the Polish Academy of Sciences and Art and a member of European DANA Alliance for Brain (EDAB). He is also a member of Central/Eastern European Region (CEERC) of IBRO and the Society for Neuroscience. His research interests have been focused on a role of opioid peptides in physiology and pharmacology of the CNS. More recently, his research has been concentrated on molecular and cellular mechanisms of opioid action with special emphasis on gene expression and genetic mechanisms of opioid addiction. He has published over 150 peer-reviewed research papers in international journals.

Curriculum Vitae


1962-1967 Department of Automatics and Electronics Academy of Mining, Kraków, M.S. awarded

1966-1970 Institute of Psychology, Jagiellonian University, Cracow

1970-1975 Department of Neuropharmacology, Institute of Pharmacology, PAS,Cracow Ph. D. awarded 1975-(Pharmacology)

1986 Nencki Institute for Experimental Biology, Warsaw, DSc in Neuropharmacology.

1992 Professor of Med. Sci. - Institute of Pharmacology PAS, Cracow

1999 Professor- Institute of Applied Psychology, Jagiellonian University, Cracow


1969-1975 Pre-Doctoral Fellow, Institute of Pharmaco- logy, Cracow

1975-1977 Post-Doctoral Fellow, Department of Neuro- pharmacology, Institute of Pharmacology, Cracow

1977-1986 Assistant Professor, Institute of Pharmaco- logy, Cracow (on leave 1977-1979)

1977-1979 Visiting Scientist, Department of Neuropharma- cology, Max-Planck Institute of Psychiatry, Munich

1987- Associate Professor, Institute of Pharmaco- logy Polish Academy of Sciences

1987 Visiting Scientist, Institute of Mental Health Ann Arbor, Michigan

1989 Head of Department of Neuropeptide Research Institute of Pharmacology PAS, Cracow

1991 Professor at Institute of Pharmacology, Polish Academy of Sciences, Kraków

1993- present Head, Department of Molecular Neuropharmacology, Institute of Pharmacology PAS, Cracow.

1996-1998 Department of Molecular and Cellular Biology PAS, Warsaw.

1999-present Professor at Institute of Applied Psychology Jagiellonian University, Cracow

2003 Head, Deapartment of Neurobiology, Institute of Applied Psychology, Jagiellonian University, Cracow


1975 Polish Academy of Sciences award in medicine

1977-1979 Max-Planck Stipend

1986 Supniewski's award in Pharmacology

1987 University of Ann Arbor Stipend

1993 Polish Academy of Science award in medicine

1994 Fullbright stipend

1998 T. Browicz award in medicine, Polish Academy of Art and Sciences



Polish Neuroscience Society(President elect 2006-2008)

Polish Pharmacological Society

European Neuropeptide Club

International Narcotic Research Conference

Scientific Commitee, Institute of Pharmacol.


International Advisory Board, International

Institute Of Molecular and Cellular Biology,


Committee of Neurobiology,Polish Academy. Of Sciences (v-ce President).

Editorial Board, Life Sciences.

Editorial Board, European Journal of Pharmacology.

Selected Publications


  • 1. PRZEWLOCKI R. Lason W., Konecka A., Gramsch C., Herz A., Reid L.: The opioid peptides dynorphin, circadian rhythms and starvation. Science 1983, 219, 71-72.
  • 2. Stein C., Hassan A.H.S., PRZEWLOCKI R., Gramsch C., Peter K., Herz A.: Opioids from immunocytes interact with receptors on sensory nerves to inhibit nociception in inflammation. Proc Natl Acad Sci USA 1990 87:5935-5939.
  • 3. Lason W., Przewlocka B., PRZEWLOCKI R.: The prodynorphin system in the rat hippocampus is differentially influenced by kainic acid and pentetrazole. Neuroscience 1992 57:357-362.
  • 4. Przewlocka B., Lason W., PRZEWLOCKI R.: Time-dependent changes in the activity of opioid systems in the spinal cord of monoarthritic rats: a release and in situ hybridization study. Neuroscience 1992 46:209-216.
  • 5. PRZEWLOCKI R., Hassan A.H.S., Lason W., Epplen C., Herz A., Stein G.: Gene expression and localization of opioid peptides in immune cells of inflamed tissue: functional role in antinociception. Neuroscience 1992 48:491-500.
  • 6. Majeed N.H., Przewlocka B., Machelska H., PRZEWLOCKI R.: Inhibition of nitric oxide synthase attenuates the development of morphine tolerance and dependence in mice. Neuropharmacology 1994 33:189-192.
  • 7. Kaminska B., Filipkowski R.K., Zurkowska G., Lason W., PRZEWLOCKI R., Kaczmarek L.: Dynamic changes in the composition of the AP-1 transcription factor DNA-binding activity in rat brain following kainate-induced seizuresand cell death. Eur. J. Neurosci. 1994 6:1558-1566.
  • 8. PRZEWLOCKI R., Kaminska B., Lukasiuk K., Nowicka D.Z., Przewlocka B., Kaczmarek L., Lason W.: Seizure related changes in the regulation of opioid genes and transcription factors in the dentate gyrus of rat hippocampus. Neuroscience 1995 68:73-81.
  • 9. Bilecki W., Okruszek A., PRZEWLOCKI R.: The effect of antisense oligodeoxynucleotides on nitric oxide secretion from macrophage-like cells . Antisense Nucleic Acid Drug Dev 1997 7(6):531-537.
  • 10. Turchan J., Przewlocka B. Lason W., PRZEWLOCKI R. Effects of repeated psychostimulant administration on the prodynorphin system activity and kappa opioid receptor density in the rat brain. Neuroscience 1998 85(4):1051-1059.
  • 11. PRZEWLOCKI R., Parsons K.L., Sweeney D.D., Trotter C., Netzeband J.G., Siggins G.R., Gruol D.L.: Opioid enhancement of calcium oscillations and burst events involving NMDA receptors and L-type calcium channels in cultured hippocampal neurons. J Neurosci 1999, 19(22):9705-15
  • 12. Bilecki W., Bargiela-Wawrzczak A., PRZEWLOCKI R.: Activation of AP-1 and CRE-dependent gene expression via μ-opioid receptor. J. Neurochem 2004 ; 90(4):874-82
  • 13. Rodriguez Parkitna J.M., Bilecki W, P. Mierzejewski, R. Stefanski, Ligeza A., Bargiela A., Ziólkowska B., Kostowski W., PRZEWLOCKI R.: Differential gene expression in rat amygdala after morphine self- administration. J. Neurochem. 2004;91(1):38-48.
  • Przewlocki R. Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology. 2005; 30(1):80-9. 14. Schneider T,
  • 15. Ziolkowska B, Gieryk A, Bilecki W, Wawrzczak-Bargiela A, Wedzony K, Chocyk A, Danielson PE, Thomas EA, Hilbush BS, Sutcliffe JG, Przewlocki R.: Regulation of α-synuclein gene expression in limbic and motor brain regions of morphine-treated mice. J. Neurosci.. ( in press).

Prof. Dr. hab Ryszard Przewlocki

Zaklad Neurofarmakologii Molekularnej
Instytut Farmakologii PAN
Smetna 12
31-343 Kraków, Polska